Does the media prefer AURA or PLX?

In the previous week, Aura Biosciences had 3 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 4 mentions for Aura Biosciences and 1 mentions for Protalix BioTherapeutics. Protalix BioTherapeutics' average media sentiment score of 1.49 beat Aura Biosciences' score of 0.70 indicating that Protalix BioTherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protalix BioTherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PHAR or PLX?

In the previous week, Pharming Group had 7 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 8 mentions for Pharming Group and 1 mentions for Protalix BioTherapeutics. Protalix BioTherapeutics' average media sentiment score of 1.49 beat Pharming Group's score of 0.32 indicating that Protalix BioTherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharming Group 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Protalix BioTherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PLX or CLYM?

In the previous week, Climb Bio had 15 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 16 mentions for Climb Bio and 1 mentions for Protalix BioTherapeutics. Protalix BioTherapeutics' average media sentiment score of 1.49 beat Climb Bio's score of 0.58 indicating that Protalix BioTherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protalix BioTherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Climb Bio 3 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PLX or RIGL?

In the previous week, Rigel Pharmaceuticals had 24 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 25 mentions for Rigel Pharmaceuticals and 1 mentions for Protalix BioTherapeutics. Protalix BioTherapeutics' average media sentiment score of 1.49 beat Rigel Pharmaceuticals' score of 0.27 indicating that Protalix BioTherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protalix BioTherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rigel Pharmaceuticals 7 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Protalix BioTherapeutics (PLX) Competitors

$2.48 +0.02 (+0.81%)

As of 04:00 PM Eastern

Compare

PLX vs. DRUG, AURA, PHAR, CLYM, and RIGL

Should you buy Protalix BioTherapeutics stock or one of its competitors? Protalix BioTherapeutics's main competitors and comparable companies include Bright Minds Biosciences (DRUG), Aura Biosciences (AURA), Pharming Group (PHAR), Climb Bio (CLYM), and Rigel Pharmaceuticals (RIGL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Protalix BioTherapeutics compare to Bright Minds Biosciences?

Bright Minds Biosciences (NASDAQ:DRUG) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.

Bright Minds Biosciences has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Bright Minds Biosciences' return on equity of -20.58% beat Protalix BioTherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-20.58%	-20.25%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

Protalix BioTherapeutics has higher revenue and earnings than Bright Minds Biosciences. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A
Protalix BioTherapeutics	$76.38M	2.62	$8.31M	$0.18	13.78

Bright Minds Biosciences has a beta of -5.27, indicating that its share price is 627% less volatile than the broader market. Comparatively, Protalix BioTherapeutics has a beta of 0.02, indicating that its share price is 98% less volatile than the broader market.

Bright Minds Biosciences presently has a consensus target price of $143.83, indicating a potential upside of 78.03%. Protalix BioTherapeutics has a consensus target price of $12.00, indicating a potential upside of 383.87%. Given Protalix BioTherapeutics' higher probable upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Bright Minds Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

40.5% of Bright Minds Biosciences shares are held by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 42.7% of Bright Minds Biosciences shares are held by insiders. Comparatively, 6.7% of Protalix BioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Bright Minds Biosciences had 3 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 4 mentions for Bright Minds Biosciences and 1 mentions for Protalix BioTherapeutics. Protalix BioTherapeutics' average media sentiment score of 1.49 beat Bright Minds Biosciences' score of 0.29 indicating that Protalix BioTherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bright Minds Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Protalix BioTherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Bright Minds Biosciences and Protalix BioTherapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Protalix BioTherapeutics compare to Aura Biosciences?

Aura Biosciences (NASDAQ:AURA) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Protalix BioTherapeutics has higher revenue and earnings than Aura Biosciences. Aura Biosciences is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A
Protalix BioTherapeutics	$76.38M	2.62	$8.31M	$0.18	13.78

In the previous week, Aura Biosciences had 3 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 4 mentions for Aura Biosciences and 1 mentions for Protalix BioTherapeutics. Protalix BioTherapeutics' average media sentiment score of 1.49 beat Aura Biosciences' score of 0.70 indicating that Protalix BioTherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aura Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protalix BioTherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

96.8% of Aura Biosciences shares are held by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 1.9% of Aura Biosciences shares are held by company insiders. Comparatively, 6.7% of Protalix BioTherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Aura Biosciences has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-78.12%	-64.08%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

Aura Biosciences currently has a consensus price target of $20.50, indicating a potential upside of 166.23%. Protalix BioTherapeutics has a consensus price target of $12.00, indicating a potential upside of 383.87%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Protalix BioTherapeutics is more favorable than Aura Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Aura Biosciences has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market. Comparatively, Protalix BioTherapeutics has a beta of 0.02, indicating that its share price is 98% less volatile than the broader market.

Summary

Protalix BioTherapeutics beats Aura Biosciences on 9 of the 15 factors compared between the two stocks.

How does Protalix BioTherapeutics compare to Pharming Group?

Pharming Group (NASDAQ:PHAR) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Pharming Group has a net margin of 2.51% compared to Protalix BioTherapeutics' net margin of -21.03%. Pharming Group's return on equity of 3.40% beat Protalix BioTherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	2.51%	3.40%	1.90%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

0.0% of Pharming Group shares are owned by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by company insiders. Comparatively, 6.7% of Protalix BioTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Protalix BioTherapeutics has lower revenue, but higher earnings than Pharming Group. Protalix BioTherapeutics is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$376.13M	2.14	$2.85M	$0.12	94.58
Protalix BioTherapeutics	$76.38M	2.62	$8.31M	$0.18	13.78

In the previous week, Pharming Group had 7 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 8 mentions for Pharming Group and 1 mentions for Protalix BioTherapeutics. Protalix BioTherapeutics' average media sentiment score of 1.49 beat Pharming Group's score of 0.32 indicating that Protalix BioTherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharming Group	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Protalix BioTherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pharming Group presently has a consensus price target of $38.67, indicating a potential upside of 240.68%. Protalix BioTherapeutics has a consensus price target of $12.00, indicating a potential upside of 383.87%. Given Protalix BioTherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Protalix BioTherapeutics is more favorable than Pharming Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Pharming Group has a beta of -0.01, suggesting that its stock price is 101% less volatile than the broader market. Comparatively, Protalix BioTherapeutics has a beta of 0.02, suggesting that its stock price is 98% less volatile than the broader market.

Summary

Protalix BioTherapeutics beats Pharming Group on 9 of the 16 factors compared between the two stocks.

How does Protalix BioTherapeutics compare to Climb Bio?

Protalix BioTherapeutics (NYSE:PLX) and Climb Bio (NASDAQ:CLYM) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Climb Bio has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat Climb Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
Climb Bio	N/A	-31.79%	-30.79%

Protalix BioTherapeutics has higher revenue and earnings than Climb Bio. Climb Bio is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$76.38M	2.62	$8.31M	$0.18	13.78
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A

Protalix BioTherapeutics has a beta of 0.02, meaning that its stock price is 98% less volatile than the broader market. Comparatively, Climb Bio has a beta of 0.08, meaning that its stock price is 92% less volatile than the broader market.

Protalix BioTherapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 383.87%. Climb Bio has a consensus price target of $22.75, suggesting a potential upside of 68.02%. Given Protalix BioTherapeutics' higher probable upside, equities analysts plainly believe Protalix BioTherapeutics is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

16.5% of Protalix BioTherapeutics shares are owned by institutional investors. Comparatively, 69.8% of Climb Bio shares are owned by institutional investors. 6.7% of Protalix BioTherapeutics shares are owned by company insiders. Comparatively, 2.6% of Climb Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Climb Bio had 15 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 16 mentions for Climb Bio and 1 mentions for Protalix BioTherapeutics. Protalix BioTherapeutics' average media sentiment score of 1.49 beat Climb Bio's score of 0.58 indicating that Protalix BioTherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protalix BioTherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Climb Bio	3 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Protalix BioTherapeutics beats Climb Bio on 8 of the 15 factors compared between the two stocks.

How does Protalix BioTherapeutics compare to Rigel Pharmaceuticals?

Protalix BioTherapeutics (NYSE:PLX) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

Rigel Pharmaceuticals has a net margin of 116.30% compared to Protalix BioTherapeutics' net margin of -21.03%. Rigel Pharmaceuticals' return on equity of 22.95% beat Protalix BioTherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
Rigel Pharmaceuticals	116.30%	22.95%	17.19%

Rigel Pharmaceuticals has higher revenue and earnings than Protalix BioTherapeutics. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$76.38M	2.62	$8.31M	$0.18	13.78
Rigel Pharmaceuticals	$294.28M	2.62	$367.02M	$16.32	2.55

Protalix BioTherapeutics has a beta of 0.02, meaning that its stock price is 98% less volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market.

Protalix BioTherapeutics currently has a consensus target price of $12.00, indicating a potential upside of 383.87%. Rigel Pharmaceuticals has a consensus target price of $54.50, indicating a potential upside of 30.82%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Rigel Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

16.5% of Protalix BioTherapeutics shares are owned by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 6.7% of Protalix BioTherapeutics shares are owned by company insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Rigel Pharmaceuticals had 24 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 25 mentions for Rigel Pharmaceuticals and 1 mentions for Protalix BioTherapeutics. Protalix BioTherapeutics' average media sentiment score of 1.49 beat Rigel Pharmaceuticals' score of 0.27 indicating that Protalix BioTherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protalix BioTherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rigel Pharmaceuticals	7 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Rigel Pharmaceuticals beats Protalix BioTherapeutics on 13 of the 16 factors compared between the two stocks.

Get Protalix BioTherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLX vs. The Competition

Export

Metric	Protalix BioTherapeutics	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$199.82M	$3.72B	$7.06B	$24.19B
Dividend Yield	N/A	3.76%	2.58%	3.69%
P/E Ratio	-19.08	9.13	269.75	29.08
Price / Sales	2.62	1,274.20	652.34	13.90
Price / Cash	17.80	44.95	28.89	19.37
Price / Book	5.28	17.66	11.27	4.91
Net Income	$8.31M	-$13.25M	$3.45B	$1.06B
7 Day Performance	6.90%	5.36%	3.56%	1.30%
1 Month Performance	1.64%	-1.74%	-0.58%	2.29%
1 Year Performance	61.04%	61.36%	77.52%	19.89%

Protalix BioTherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLX Protalix BioTherapeutics	3.2333 of 5 stars	$2.48 +0.8%	$12.00 +383.9%	+59.7%	$199.82M	$76.38M	N/A	200
DRUG Bright Minds Biosciences	2.5236 of 5 stars	$77.35 +4.8%	$143.83 +86.0%	+104.4%	$752.62M	N/A	N/A	N/A	Upcoming Earnings
AURA Aura Biosciences	2.9609 of 5 stars	$7.15 +1.6%	$20.50 +186.7%	+17.5%	$739.24M	N/A	N/A	50	Upcoming Earnings Analyst Upgrade
PHAR Pharming Group	3.7315 of 5 stars	$10.26 +4.5%	$38.67 +276.9%	-18.0%	$726.20M	$376.13M	85.50	280	Analyst Forecast Gap Up
CLYM Climb Bio	2.4377 of 5 stars	$12.56 +6.4%	$22.08 +75.8%	+723.5%	$719.19M	N/A	N/A	9	Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:PLX) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Protalix BioTherapeutics (PLX) Competitors

PLX vs. DRUG, AURA, PHAR, CLYM, and RIGL

How does Protalix BioTherapeutics compare to Bright Minds Biosciences?

Summary

How does Protalix BioTherapeutics compare to Aura Biosciences?

Summary

How does Protalix BioTherapeutics compare to Pharming Group?

Summary

How does Protalix BioTherapeutics compare to Climb Bio?

Summary

How does Protalix BioTherapeutics compare to Rigel Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLX vs. The Competition

Protalix BioTherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Protalix BioTherapeutics (PLX) Competitors

PLX vs. DRUG, AURA, PHAR, CLYM, and RIGL

How does Protalix BioTherapeutics compare to Bright Minds Biosciences?

Is DRUG or PLX more profitable?

Which has higher earnings and valuation, DRUG or PLX?

Which has more volatility & risk, DRUG or PLX?

Do analysts prefer DRUG or PLX?

Do insiders and institutionals hold more shares of DRUG or PLX?

Does the media refer more to DRUG or PLX?

Summary

How does Protalix BioTherapeutics compare to Aura Biosciences?

Which has preferable valuation and earnings, AURA or PLX?

Does the media prefer AURA or PLX?

Do insiders & institutionals hold more shares of AURA or PLX?

Is AURA or PLX more profitable?

Do analysts prefer AURA or PLX?

Which has more volatility and risk, AURA or PLX?

Summary

How does Protalix BioTherapeutics compare to Pharming Group?

Is PHAR or PLX more profitable?

Do institutionals and insiders believe in PHAR or PLX?

Which has preferable valuation and earnings, PHAR or PLX?

Does the media refer more to PHAR or PLX?

Do analysts rate PHAR or PLX?

Which has more risk and volatility, PHAR or PLX?

Summary

How does Protalix BioTherapeutics compare to Climb Bio?

Is PLX or CLYM more profitable?

Which has stronger valuation & earnings, PLX or CLYM?

Which has more risk and volatility, PLX or CLYM?

Do analysts prefer PLX or CLYM?

Do institutionals & insiders hold more shares of PLX or CLYM?

Does the media refer more to PLX or CLYM?

Summary

How does Protalix BioTherapeutics compare to Rigel Pharmaceuticals?

Is PLX or RIGL more profitable?

Which has stronger valuation & earnings, PLX or RIGL?

Which has more volatility & risk, PLX or RIGL?

Do analysts recommend PLX or RIGL?

Do insiders & institutionals believe in PLX or RIGL?

Does the media favor PLX or RIGL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLX vs. The Competition

Protalix BioTherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools